1. Home
  2. MMM vs REGN Comparison

MMM vs REGN Comparison

Compare MMM & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 3M Company

MMM

3M Company

HOLD

Current Price

$178.96

Market Cap

82.6B

Sector

Health Care

ML Signal

HOLD

Logo Regeneron Pharmaceuticals Inc.

REGN

Regeneron Pharmaceuticals Inc.

HOLD

Current Price

$834.04

Market Cap

68.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MMM
REGN
Founded
1902
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
82.6B
68.8B
IPO Year
2006
1995

Fundamental Metrics

Financial Performance
Metric
MMM
REGN
Price
$178.96
$834.04
Analyst Decision
Hold
Buy
Analyst Count
8
25
Target Price
$170.88
$830.16
AVG Volume (30 Days)
2.4M
739.9K
Earning Date
04-21-2026
04-29-2026
Dividend Yield
2.17%
0.55%
EPS Growth
N/A
8.19
EPS
3.01
18.95
Revenue
$24,948,000,000.00
$5,872,227,000.00
Revenue This Year
$1.78
$12.45
Revenue Next Year
$3.17
$10.13
P/E Ratio
$59.27
$43.63
Revenue Growth
1.52
20.82
52 Week Low
$139.34
$541.00
52 Week High
$184.90
$844.92

Technical Indicators

Market Signals
Indicator
MMM
REGN
Relative Strength Index (RSI) 55.98 76.50
Support Level $162.70 $732.04
Resistance Level $184.79 N/A
Average True Range (ATR) 3.42 19.45
MACD -1.10 2.17
Stochastic Oscillator 27.69 87.52

Price Performance

Historical Comparison
MMM
REGN

About MMM 3M Company

3M, a multinational conglomerate founded in 1902, sells tens of thousands of products ranging from sponges to respirators. The firm is well known for its extensive research and development capabilities, and it is a pioneer in inventing new use cases for its proprietary technologies. 3M is organized across three business segments: safety and industrial (representing around 44% of revenue), transportation and electronics (36%), and consumer (20%). The firm recently spun off its healthcare business, now known as Solventum. Nearly half of 3M's revenue comes from outside the Americas.

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.

Share on Social Networks: